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Hyperthermia
F. K. Storm, MD*

This report describes the history of hyperthermia and reviews current forms of treatment at both low (42°-43°C)
and higher (<45°C) temperatures. Hyperthermia treatment
at low temperatures includes fluid immersion and irrigation, regional perfusion with heated fluids, and electromagnetic radiofrequency waves. Low-temperature hyperthermia has also been combined with radiation therapy
and with chemotherapy in recent clinical trials. At higher
temperatures, we and other investigators have also had
promising, preliminary results in treating tumors safely.
With the specialized radiofrequency instrumentation we
have developed to apply hyperthermia at any depth with-
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out preferential surface tissue heating, further clinical investigation of both superficial and deep internal solid
tumors is now possible.
Recent data suggest that hyperthermia may be an especially effective form of therapy for larger tumors that resist
standard forms of treatment. Clinical trials are now underway to determine the most therapeutic dose/time regimen,
to determine toxicity and therapeutic enhancement ratios
of combined chemotherapy and x-irradiation with hyperthermia, and to evaluate any changes in the host immune
system with such therapies.

heat in cancer treatment dates back to the
ancients with the application of red-hot irons by Ramajama
(2000 BC), Hippocrates (400 BC), and Galen (200 AD). In
more recent times, Westermark (1898) placed hot-water
circulating cisterns into advanced carcinomas ofthe uterus
and found palliative shedding of some tumors. Coley
(1927) introduced " t o x i n " therapy for cancer, but stated
that responses were associated w i t h temperatures of
39°-40°C of several days' duration, suggesting that the
febrile reaction might have been caused by the tumericidal
agent. Simultaneously, Keating-Hart and Doyen (1910) introduced electrocoagulation of tumors, which is still in use
today. Warren (1933) was one ofthe first to apply heat from
infrared and high-frequency currents to tumors and found
remissions of some cancers. With the subsequent development and popularity of x-irradiation therapy, hyperthermia
research was all but abandoned until modern times when
the selective thermosensitivity of tumor cells was more fully
appreciated.

At temperatures between 41°-45°C (106°-113° F), cancer
cells are slightly more sensitive to heat than their normal
cell counterparts. In vitro and in vivo tumor models have
shown irreversible damage and complete regression of
various tumors at 42°-45°C, while normal cells were killed
at temperatures at least one degree higher, or more than
twice the duration of heating (1-4).
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Hyperthermia alters both DNA and RNA synthesis and
depresses cellular enzymatic systems required for cell metabolism and division. Its major mode of action may be to
increase cell and lysosome membrane permeability, caus-
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Heat causes progressive necrosis to tumor cells at these
temperatures but not in stromal or vascular cells within
tumors, nor in normal surrounding tissues (5). Autolytic disintegration of heat-damaged cells is followed by a marked
increase in connective tissue stroma and scar formation (6).
Interestingly, this process occurs in tissue cultures of tumorderived and tumor-producing cells, but not in normal and
non-tumor-producing cells. When a cell subline derived
from a non-tumor-producing line acquires high tumorproducing capacity, it also acquires greater thermosensitivity. Thus, malignant potential, both in vivo and in vitro,
is accompanied by decreased thermotolerance (7-8).
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ing selective internal destruction of the cancer cell. Cells
that are less well oxygenated seem to be most vulnerable to
thermic injury.

Modern Concepts of
Low-Temperature Hyperthermia
Hyperthermia has been applied by various means, including fluid immersion and irrigation, regional perfusion with
heated fluids, and by electromagnetic radiofrequency
waves.
All frequencies of radiofrequency waves appear to heat
tissues in a similar way. Energy is transferred into tissue by
field interaction that causes ions in the tissue to oscillate or
produces changes in the magnetic orientation of molecules, which are locally converted into heat. Because the
energy of a shortwave or microwave quantum is only about
10'' eV, it cannot produce ionization or excitation. The
biological effects of radiofrequency waves are primarily
and perhaps solely due to heat production. However, the
absorption and penetration characteristics of electromagnetic waves are markedly dependent upon tissue composition and interfaces (i.e., skin/muscle/fat/bone). Moreover,
the depth of penetration is often limited. Incident energy
absorption is a function of tissue resistance, so that tissues
with high values (skin, subcutaneous tissue, bone) preferentially absorb heat in amounts 10-150 times greater than
tissue with low values (muscle, organs, tumors). Therefore,
if skin or subcutaneous tissue must be penetrated to heat
deeper tissue, a high and potentially dangerous degree of
surface energy deposition-would be needed to produce
deep heat effectively.
At present, satisfactory heating is limited to depths of 2-3
cm with commercially available diathermy apparatus. In
an attempt to overcome this limitation, several investigators
have designed specialized equipment in the range of 915
MHz and 2450 M H z microwave bands. However, even
w i t h surface c o o l i n g , d o c u m e n t e d temperatures of
42°-44°C have been possible only at 2-3 cm depth, with
the thermal gradient continuously decreasing as depth
increases. For this reason, clinical trials wfth standard
microwave techniques have been limited to superficial
tumors. In an effort to produce deep internal hyperthermia,
several approaches have been used, particularly limb perfusion, total body h y p e r t h e r m i a , and c o m b i n a t i o n
therapies.
Isolated limb perfusion
In 1967, Caval iere performed regional limb perfusions with
pre-warmed blood at 41.5°-43.5°C in 22 patients wfth
large, recurrent, or single metastatic cancers localized in

the extremities. All evidence of gross tumor disappeared in
10 patients, five had regressions, three failed to respond,
and four could not be evaluated. The complication rate was
high, with six deaths and three immediate amputations;
however, massive tumor necrosis was demonstrated (4).
Total body hyperthermia
Pettigrew, in 1974, reported on 38 terminal cancer cases
treated by total body hyperthermia at 41.8°C for an average
of four hours, which was applied by emersion in molten
wax. An objective response, weight gain, or relief from
pain, as well as measured tumor regression or histologic
evidence of necrosis, was seen in 18 of 38 cases, wfth
four patients dying from disseminated intravascular coagulation (9).
Larkin and Edwards, in 1976, reported their experience
with total body hyperthermia applied by a water-circulating suit. Nineteen patients were maintained at 41.5°-42°C
for two to five hours, with an objective tumor response
noted in 70%. Complications included one death, transient
cardiac arrhythmias in 15%, superficial burns in 15%, and
transient respiratory distress in 11%, which have been
attributed to the seven to eight hours of anesthesia time
required to raise and maintain body temperatures in these
critically ill patients (11).
The rmo rad iot he rapy
Hyperthermia has been combined with radiation therapy
in the hope of producing a synergistic and augmented
response. Since hypoxic cells are more radioresistant than
aerobic cells (11), several investigators have concluded that
hypoxic cells may be at least as sensftive to hyperthermia
as aerobic cells. Others have suggested that the primary
effect of hyperthermia is to inhibit cellular recovery from
sublethal radiation damage (12).
When tumor cells were exposed to hyperthermia followed
by 600 rad radiation, the result was a three-log increase in
cells killed as compared to their survival at 37°C to 43°C.
Clinical doses for local and regional treatment wfth the
combined treatment may lie in the range of 200-600
rad/fraction (13).

Clinical trials
In 1977, K im reported his experience using hyperthermia
and radiation for cutaneous cancers in man. With fractionated doses of 800-2400 rad followed by 43.5°C surface
heating by water bath or microwaves, 7 of 10 patients
showed significant prolonged benefits wfth combination
therapy when compared to radiation alone (14).
Hornback has treated 70 patients with advanced malignancy with a combination of microwave (heating) and
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standard radiation. Of 21 patients who received a full
course of therapy, 16 (80%) had complete regression of all
local tumor, and nine of them remained free of disease
from nine to 14 months (15).
The Radiation Therapy Oncology Croup has recently established a controlled study among 14 institutions to explore the efficacy of such combined therapy. Phase 1
studies suggest that effective thermal doses are probably in
the range of 43°-45°C, combined with higher doses of
radiation equivalent to 4,000 rad in four weeks (Boone
MLN, Gerner EW, personal communication, 1976).
The rmoc hemothe rapy
The combination of hyperthermia and chemotherapy has
also been investigated, since heat is thought to alter tumor
cell membrane permeability and enhance uptake of
chemotherapeutic agents.
In 1970, Giovanella found a four-log kill in leukemia cells
at 42°C in three hours. With the addition of dihydroxybutylaldehyde, a 100-fold kill enhancement was observed
w i t h no increase in toxicity. D L - g l y c e r a l y d e h y d e ,
melphalan, sodium oxyamate, and actinomycin-D were
also active in combination with heat (16). In vitro data also
suggest benefits from hyperthermia c o m b i n e d w i t h
adriamycin (17).
In 1976, Goss reported on the survival of four human
fibroblast strains and seven melanoma cell lines after exposure to various concentrations of melphalan alone and
in combination with heat at 42°C for four hours. He found
that combined treatment was not only synergistic but increased the differential between fibroblast and melanoma
lines (18).
When Stehlin, et al treated locally recurrent and intransit
melanoma ofthe extremities using hyperthermic limb perfusion, they found an increased response from 35% to 80%
by adding heat (41°C) to melphalan perfusion (19).

tolerance becomes the prime consideration (1,4,7).
Therapeutic hyperthermia in this higher temperature range
was not thought feasible until the realization that some
solid tumors might act as a heat reservoir and retain heat
due to abnormal vascularity and relatively poor blood flow.
When Shibata and MacLean evaluated cancers in man,
they found that the blood supply was poorer in all tumors
studied (21). Using isotope dilution techniques, LeVeen
found that tumor blood flow was only 2-15% that of
surrounding tissue and concluded that tumors retain more
heat than normal tissue whose adaptive vasculature allows
heat dissipation (22).
Our evaluation of thermal tolerance on animal skin, extremities, and viscera supported the safety of temperatures
o f < 4 5 ° C (23). Interestingly, when normal animal muscle
reaches 43°-44°C, spontaneous cooling occurs that maintains the tissue well below its thermal tolerance limit. This
phenomenon, which has been observed by others, supports the theory of normal tissue adaptation to hyperthermia that is consistent with augmented blood flow (22).
When external, radiofrequency hyperthermia is applied to
canine normal viscera, no selective heating ofany normal
organ occurs.
Animal tumor investigations
Using shortwave-induced hyperthermia, Dickson reported
that 7 of 10 rabbits bearing VX2 carcinoma had complete
tumor regression with cure ofthe host. The temperature of
skin and normal muscle remained 3°-4°C lowerthan minimal tumor temperatures, and no injury occurred (23).
In our experience, hyperthermia applied to spontaneously
arising dog tumors results in solid tumor heating above
45°C, with normal adjacent tissues remaining at physiologic temperatures. Moreover, when treatment ends,
heated tumors dissipate heat much more slowly than adjacent normal muscle, which shows that normal tissues and
tumors differ in their capacity to dissipate incident heat.
Human clinical trials

Modern Concepts of High-Temperature
Local Tumor Hyperthermia
Most studies so far have dealt with moderate hyperthermia
of 42°-43°C alone or c o m b i n e d w i t h x - i r r a d i a t i o n or
chemotherapy, based upon the evidence of selective thermal sensitivity of tumor cells. Lethal temperature/exposure
time relationships have been established for many cell
lines. However, several investigators have found that at
temperatures approaching 45°C a linear kill takes place
dueto progressive and irreversible protein denaturation. At
such high temperatures the differential susceptibility between malignant and normal cells decreases, and host

LeVeen applied shortwave hyperthermia to 21 patients and
produced tumor temperatures over 46°C, which is 8°-10°C
higher than in adjacent normal tissue. Tumor necrosis or
substantial regression of cancer was noted in each case
with minimal destruction of normal tissue. However, he
found that for internal tumors, it was best to transmit energy
to lesions that were surgically exposed to avoid heating
and occasional burning of surface tissues (22), as others
have experienced.
With the specialized radiofrequency instrumentation we
have developed to apply hyperthermia at any depth without preferential surface tissue heating, further clinical in-
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vestigation of both superficial and deep internal solid
tumors is now possible (23-25).
In 30 patients with 36 refractory cancers, we found that
intratumor temperatures of 42°-50PC could be achieved in
more than three-fourths, wfth virtually no injury to normal
tissues. Selective hyperthermia was possible with both
primary and metastatic solid tumors and appeared to be
independent of tumor histology. Intratumor heating above
45°C was achieved most often in tumors < 5cm in diameter. Most of the tumors that could not be heated to 45°C
displayed physiologic adaptation to heat, similar to that of
adjacent normal tissues.
While standard methods of cancer therapy (surgery, xirradiation, chemotherapy) are most effective for small
tumors, our data suggest that hyperthermia may be
uniquely effective against larger tumors. Tumor necrosis
was marked in lesions heated<50°C for 15-60 minutes on
one or more occasions. Such treatment caused rapid coagulative necrosis and vascular thrombosis. Superficial tumors generally w o u l d slough w i t h i n several days of
therapy. However, effectively heated visceral tumors would
remain intact with little change in size and with no evidence of systemic tumor breakdown products by serum
creatinine, urate, or urinary protein determinations. Serial
biopsies of these internal tumors revealed few functional
vessels and progressive tumor replacement by scar. All
superficial normal tissues and viscera that were evaluated
had the capacity to adapt to heat and, with proper radiofrequency application, could be maintained within a physiologically safe temperature range (23-26).
Hyperthermic immune enhancement
Several investigators have suggested that selective tumor
regression after hyperthermia may be due, in part, to some
augmentation of the immune system, although few studies

are available. Goldenberg found that the growth of human
colonic tumors in hamster cheek pouches was inhibited
after he applied shortwave diathermy heating; the growth
of contralateral, presumably normothermic, cheek pouch
tumors was also inhibited (20). Hahn found that sarcomas
implanted in mice were highly sensitive to cure by radiofrequency heating. However, cell-kill as assessed by cloning
efficiency of treated and immediately excised tumors was
insufficient to account for the in vivo cures. This suggested
that delayed killing might be the result of stimulation of a
tumor-directed immune response, secondary to the direct
effects of low or high dose hyperthermia.

Future Prospects
The results of animal research and initial clinical trials,
associated with our development of safe and effective
equipment, indicate that hyperthermia may become a potentially useful form of local cancer therapy when fully
evaluated. Clinical trials are now underway to determine
the most therapeutic dose/time regimen, to determine toxicity and therapeutic enhancement ratios of combined
chemotherapy and x-irradiation with hyperthermia, and to
evaluate any changes in the host immune system with such
therapies.
Patients with advanced cancer that resists standard methods of therapy, or those wfth cancers for which no standard
therapy exists, are candidates for experimental hyperthermic therapy.
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